Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health provided a comprehensive update on its progress during 2021, highlighting critical milestones in the development of its plant-based drug pipeline. Key achievements include the ongoing OnTarget Phase 3 clinical trial for crofelemer, FDA conditional approval for Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and a significant revenue increase for Mytesi, which saw net revenues of approximately $2.1 million in Q4 2021, marking a 230% increase from Q3 2021. Despite these advances, the company reported a substantial net loss of $52.6 million for 2021.
Jaguar Health (NASDAQ:JAGX) has announced an investor webcast scheduled for March 14, 2022, at 8:30 AM ET to discuss its Q4 2021 financials and corporate updates. The company plans to file its Annual Report on March 11, 2022, for the fiscal year ending December 31, 2021. Jaguar focuses on developing plant-based, non-opioid prescription medicines for gastrointestinal distress. Their crofelemer drug candidate is being evaluated in a pivotal Phase 3 clinical trial. For more information, visit jaguar.health.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a treatment forum for veterinarians on March 6, 2022, during the Western Veterinary Conference in Las Vegas. The forum will discuss chemotherapy-induced diarrhea (CID) in dogs and feature noted oncologist Dr. Craig A. Clifford. Canalevia-CA1, the first FDA conditionally approved treatment for CID in dogs, will be highlighted. Registration is open to U.S. veterinarians and media via the Canalevia website. The event aims to address the unmet need for effective CID treatments as over half of veterinarians report CID impacting chemotherapy plans.
Jaguar Health (NASDAQ:JAGX) has applied for MUMS designation from the FDA for Canalevia™-CA2, aimed at treating exercise-induced diarrhea (EID) in dogs. This follows the conditional approval of Canalevia™-CA1 for chemotherapy-induced diarrhea (CID) in December 2021.
The MUMS designation would provide incentives for drug development, including potential federal grants and seven years of marketing exclusivity following conditional approval. This marks a significant step in expanding treatment options for veterinary care.
Jaguar Health (NASDAQ:JAGX) announced that its Italian subsidiary, Napo Therapeutics, has received Small and Medium Enterprise (SME) designation from the European Medicines Agency (EMA). This status provides financial incentives and support for the regulatory process, crucial for advancing the availability of crofelemer in Europe for treating rare diseases. SME companies have shown a high success rate of 89% for marketing authorizations, with nearly 20% of human medicines recommended for authorization in 2020 targeting rare diseases.
Jaguar Health, Inc. (NASDAQ:JAGX) has completed a major regulatory filing with the FDA for its oral plant-based drug, Canalevia, aimed at treating exercise-induced diarrhea (EID) in dogs. Following earlier conditional approval for chemotherapy-induced diarrhea, this new application may lead to approval by Q4 2022. The MUMS designation may provide financial incentives for this treatment, which is estimated to affect 5,000 to 15,000 dogs annually in the U.S. The submission process completes critical sections initiated in 2020.
Jaguar Health, Inc. (NASDAQ:JAGX) and its subsidiary Napo Pharmaceuticals announced the completion of a preclinical study on crofelemer for congenital diarrheal disorders (CDD). This research aims to support the orphan drug designation (ODD) application filed with the FDA for treating CDD in infants and children. The study results are anticipated to bolster Napo Therapeutics' rare disease business model in Europe. Crofelemer may potentially reduce morbidity related to CDD and lessen the dependence on parenteral nutrition, addressing a significant unmet medical need.
Jaguar Health (NASDAQ:JAGX) has appointed Dr. Martire Particco as Chief Medical Officer of Napo Therapeutics, focusing on expanding access to crofelemer for treating rare diseases in Europe, particularly short bowel syndrome (SBS) and congenital diarrheal disorders (CDD). Dr. Particco, who has over 30 years of experience in the pharmaceutical industry, aims to leverage his expertise in drug development and clinical trials to support the marketing authorization of crofelemer in Europe. Both the European Medicines Agency and the FDA have granted orphan-drug designations for crofelemer.
Jaguar Health announced significant advancements in its human pipeline for chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure (SBS-IF) in its recent corporate update. The company received conditional approval for Canalevia-CA1 for dogs, which launched in December 2021. In 2022, Jaguar aims to complete a Phase 3 CTD study and one for SBS-IF. The global market for SBS is expected to reach $4.6 billion by 2027, emphasizing the potential for Jaguar's products amid growing cancer treatment needs.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a treatment forum for veterinarians on January 16, 2022, focusing on chemotherapy-induced diarrhea (CID) in dogs. The event will be led by Dr. Craig A. Clifford and will discuss the burden of CID, as well as the efficacy of Canalevia-CA1, the first FDA conditionally approved treatment for CID in dogs. The forum will be held from 6 p.m. to 8 p.m. Eastern at the Veterinary Meeting & Expo (VMX) in Orlando, FL. Remote access will be available for registered attendees unable to attend in person.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
